http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 09 Oct 2026 09:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+06/27169728.html si-local-file:///var/storage/secattach/20261009/27169728.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+06/27169728.html Fri, 09 Oct 2026 09:02:00 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+ORiordan+Anne/27166966.html si-local-file:///var/storage/secattach/20261008/27166966.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+ORiordan+Anne/27166966.html Thu, 08 Oct 2026 16:04:00 -0400 JAZZ http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Lowered+to+%24296+at+RBC+Capital/27164248.html RBC Capital analyst Leonid Timashev lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $296.00 (from $299.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Lowered+to+%24296+at+RBC+Capital/27164248.html Thu, 08 Oct 2026 08:27:24 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+06++Filed+by%3A+GALA+RENEE+D/27162103.html si-local-file:///var/storage/secattach/20261007/27162103.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+06++Filed+by%3A+GALA+RENEE+D/27162103.html Wed, 07 Oct 2026 17:44:00 -0400 JAZZ http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24286+at+Truist+Securities/27157915.html Truist Securities analyst Gregory Renza raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $286.00 (from $281.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24286+at+Truist+Securities/27157915.html Wed, 07 Oct 2026 07:13:56 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+GALA+RENEE+D/27155788.html si-local-file:///var/storage/secattach/20261006/27155788.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+GALA+RENEE+D/27155788.html Tue, 06 Oct 2026 16:21:00 -0400 JAZZ http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+01++Filed+by%3A+COZADD+BRUCE+C/27149022.html si-local-file:///var/storage/secattach/20261005/27149022.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Oct+01++Filed+by%3A+COZADD+BRUCE+C/27149022.html Mon, 05 Oct 2026 16:19:00 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/27136556.html si-local-file:///var/storage/secattach/20261001/27136556.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/27136556.html Thu, 01 Oct 2026 16:32:00 -0400 JAZZ http://www.streetinsider.com/New+Coverage/Citi+initiates+Jazz+Pharmaceuticals+coverage+with+Buy+rating/27124328.html (Updated - September 30, 2026 5:05 AM EDT) <p>Citi analyst Geoff M initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $325.00.</p><p>Shares of Jazz Pharmaceuticals closed most recently at $232.35.</p><p>The analyst cited the company's oncology drug Ziihera, forecasting total sales of approximately $2.0B by 2032, compared to a consensus estimate of $1.7B. The analyst projects oncology reaching more than 50% of total sales by 2032.</p><p>Citi also noted Jazz's neuroscience franchise, which includes Xywav and Epidiolex, as a cash-generating base, and projected a five-year revenue compound annual growth rate of 8% between 2025 and 2030, http://www.streetinsider.com/New+Coverage/Citi+initiates+Jazz+Pharmaceuticals+coverage+with+Buy+rating/27124328.html Wed, 30 Sep 2026 05:05:44 -0400 JAZZ http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Assumes+Jazz+Pharmaceuticals+%28JAZZ%29+at+Buy/27098102.html (Updated - September 24, 2026 5:35 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk assumes coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $337.00.</p><p>The analyst comments "JAZZ is a global biopharmaceutical company with a commercial and research pipeline of assets in neuroscience and oncology. With the legacy commercial business annualizing at $4bn+ on the back of continued Xywav (low sodium oxybate for narcolepsy and IH) and Epidiolex (for rare epilepsy) utilization, the launches for Ziihera (zanidatamab) in HER2-expressing BTC and GEA, where the recent approval for the latter should open up a significant market opportunity, http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Assumes+Jazz+Pharmaceuticals+%28JAZZ%29+at+Buy/27098102.html Thu, 24 Sep 2026 05:35:16 -0400 JAZZ http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Assumes+Jazz+Pharmaceuticals+%28JAZZ%29+at+Buy/27098102.html (Updated - September 24, 2026 5:35 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk assumes coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $337.00.</p><p>The analyst comments "JAZZ is a global biopharmaceutical company with a commercial and research pipeline of assets in neuroscience and oncology. With the legacy commercial business annualizing at $4bn+ on the back of continued Xywav (low sodium oxybate for narcolepsy and IH) and Epidiolex (for rare epilepsy) utilization, the launches for Ziihera (zanidatamab) in HER2-expressing BTC and GEA, where the recent approval for the latter should open up a significant market opportunity, http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Assumes+Jazz+Pharmaceuticals+%28JAZZ%29+at+Buy/27098102.html Thu, 24 Sep 2026 05:35:16 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Sep+23/27096899.html si-local-file:///var/storage/secattach/20260923/27096899.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Sep+23/27096899.html Wed, 23 Sep 2026 16:15:00 -0400 JAZZ http://www.streetinsider.com/Hot+List/UBS+says+this+pharma+name+offers+a+robust+case+for+stock+outperformance/27081705.html <p>UBS is out with a note highlighting a pharma stock it expects will do well given the long-term value creation opportunity in a cancer drug developed by the company.</p><p>Jazz Pharmaceuticals (NASDAQ: JAZZ), rated Buy at UBS with a price target of $337 (up from $315), is a global biopharmaceutical company focused on developing and commercializing medicines for complex and underserved diseases. Its portfolio spans areas including neuroscience and oncology, with the company increasingly looking to Ziihera as a major driver of its future growth.</p><p>“Post recent GEA approval for Ziihera, we see a robust case for stock outperformance in the near/medium-term,” http://www.streetinsider.com/Hot+List/UBS+says+this+pharma+name+offers+a+robust+case+for+stock+outperformance/27081705.html Sat, 19 Sep 2026 10:00:00 -0400 JAZZ http://www.streetinsider.com/Hot+List+Pro/UBS+says+this+pharma+name+offers+a+robust+case+for+stock+outperformance/27081705.html <p>UBS is out with a note highlighting a pharma stock it expects will do well given the long-term value creation opportunity in a cancer drug developed by the company.</p><p>Jazz Pharmaceuticals (NASDAQ: JAZZ), rated Buy at UBS with a price target of $337 (up from $315), is a global biopharmaceutical company focused on developing and commercializing medicines for complex and underserved diseases. Its portfolio spans areas including neuroscience and oncology, with the company increasingly looking to Ziihera as a major driver of its future growth.</p><p>“Post recent GEA approval for Ziihera, we see a robust case for stock outperformance in the near/medium-term,” http://www.streetinsider.com/Hot+List+Pro/UBS+says+this+pharma+name+offers+a+robust+case+for+stock+outperformance/27081705.html Sat, 19 Sep 2026 10:00:00 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Sep+15/27062435.html si-local-file:///var/storage/secattach/20260915/27062435.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Jazz+Pharmaceuticals++++++For%3A+Sep+15/27062435.html Tue, 15 Sep 2026 09:06:00 -0400 JAZZ http://www.streetinsider.com/Mergers+and+Acquisitions/Jazz+Pharmaceuticals+acquires+Actio+Biosciences+for+%24820+million/27062253.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront, making Actio a wholly-owned subsidiary of Jazz, according to a company statement.</p> <p>The transaction adds ABS-1230, a clinical-stage oral small molecule KCNT1 inhibitor designed to treat KCNT1-related epilepsy, to Jazz's pipeline. In preclinical studies, ABS-1230 inhibited KCNT1 across all evaluable pathogenic mutations. In an early clinical proof-of-concept trial, children with KCNT1-related epilepsy who received ABS-1230 experienced seizure reductions.</p> <p>ABS-1230 has received Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations from the U.S. Food and Drug Administration and has been accepted into the http://www.streetinsider.com/Mergers+and+Acquisitions/Jazz+Pharmaceuticals+acquires+Actio+Biosciences+for+%24820+million/27062253.html Tue, 15 Sep 2026 09:01:05 -0400 JAZZ